NERV Stock — Minerva Neurosciences Inc: Cash, EV, Pipeline

Share price

$3.66

Market cap

$174.8M

Cash

$75.3M

Enterprise value

$99.5M

Balance sheet

Cash	$75.3M
Debt	$0.0M
Net cash	$75.3M
Enterprise value	$99.5M
Basic shares	47.2M shares
Fully diluted shares	86.2M shares
Fully diluted market cap	$315.5M
Cash per share	$1.60

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading NERV daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	Roluperidone	Phase 3	Negative Symptoms of Schizophrenia	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Roluperidone

Phase 3 · Active Modality: small molecule

Target 5-HT2A, sigma, α-adrenergic receptors

Partnerships n/a (company holds global commercialization rights except most of Asia)

Indications

Negative symptoms of schizophrenia (Phase 3)

Catalysts

— second half of 2027
— second half of 2028

Status note NDA submitted Aug 2022; FDA issued CRL Feb 2024. Confirmatory Phase 3 (C19) protocol submitted Dec 2025; first patient screened Mar 2026 (380 pts, 64 mg daily vs placebo). Seltorexant co-developed with Janssen was previously opted out; royalty interest sold to Royalty Pharma.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Roluperidone
Lead indication	Negative Symptoms of Schizophrenia
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07565428	Phase 3	Recruiting	Sponsor	Minerva Neurosciences	—	Negative Symptoms of Schizophrenia	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Minerva Neurosciences on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	3,288,777	+73,777	0.79%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

NERV — Minerva Neurosciences Inc